Phenylpropanolamine Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	1-2 mg/kg (or 12.5-50 mg per dog) every 8-12 hours	q8-12h	Duration: Chronic, as needed for continence; reassess periodically Notes: Start at the lower end of the dose range and titrate to effect. Maximum dose of 75 mg per dog per day is often cited. Administer with food to reduce GI upset.
Cat	PO	1-1.5 mg/kg every 12-24 hours	q12-24h	Duration: Chronic, as needed; monitor for adverse effects Notes: Use with caution due to increased sensitivity to sympathomimetics in cats. Not FDA-approved for cats; extra-label use.
Horse	PO	Not established; not recommended	N/A	Duration: N/A Notes: No established dose; not indicated.
Cattle	PO	Not established; not recommended	N/A	Duration: N/A Notes: No established dose; not indicated.
Small Ruminants	PO	Not established; not recommended	N/A	Duration: N/A Notes: No established dose; not indicated.
Rabbit	PO	Not established; not recommended	N/A	Duration: N/A Notes: No established dose; not indicated.
Bird/Poultry	PO	Not established; not recommended	N/A	Duration: N/A Notes: No established dose; not indicated.
Exotic/Other	PO	Not established; not recommended	N/A	Duration: N/A Notes: No established dose; not indicated.

Clinical Indications & Species Uses

General Indications

Urethral sphincter hypotonus (incontinence) in dogs

Dog (Canine)

Urethral sphincter hypotonus (USH) causing urinary incontinence

Pharmacology & Mechanism of Action

Drug Class: Sympathomimetic amine | Pharmacological Group: Alpha-adrenergic agonist

Mechanism of Action: Phenylpropanolamine (PPA) is a synthetic sympathomimetic amine that primarily acts as an alpha-1 adrenergic receptor agonist, with some beta-adrenergic activity. It stimulates alpha-adrenergic receptors in the smooth muscle of the urethral sphincter, leading to increased urethral tone and resistance. This action helps to control urine leakage in cases of urethral sphincter hypotonus (USH) in dogs. Additionally, PPA has weak central nervous system stimulant effects and may suppress appetite via hypothalamic action, though this is not a primary veterinary use.

Pharmacodynamics: PPA increases sympathetic tone, causing vasoconstriction, increased blood pressure, and relaxation of gastrointestinal smooth muscle. In the urinary tract, it enhances the contraction of the smooth muscle of the urethra and bladder neck, improving continence. The drug's effects are dose-dependent, with higher doses producing more pronounced alpha-adrenergic stimulation. In dogs, the onset of action for continence is typically within 1-2 hours after oral administration, with peak effects at 2-4 hours. The duration of action is approximately 8-12 hours, supporting twice-daily dosing.

⚡ Pharmacokinetics Summary

Absorption: PPA is well absorbed after oral administration in dogs and cats. Bioavailability is approximately 80-100% in dogs. Food may slightly delay absorption but does not significantly affect overall bioavailability.

Distribution: PPA is widely distributed throughout the body, crossing the blood-brain barrier to a limited extent. It is a weak base and distributes into tissues with high perfusion. The volume of distribution in dogs is approximately 2-4 L/kg.

Metabolism: PPA is metabolized in the liver primarily by oxidative deamination and conjugation. The major metabolic pathways involve CYP450 enzymes, though specific isoenzymes have not been fully characterized in veterinary species. In dogs, the metabolism is relatively rapid, with a hepatic extraction ratio that is moderate.

Excretion: PPA and its metabolites are excreted primarily in the urine. In dogs, approximately 80-90% of the dose is excreted in urine within 24 hours, with a small fraction excreted in feces. Renal clearance is dependent on urine pH; acidic urine increases excretion of the parent compound.

Half-Life: Dog: 2-3 hours; Cat: 3-4 hours (estimated); Horse: 1-2 hours (estimated)

Bioavailability: Oral bioavailability in dogs is approximately 80-100%; in cats, it is estimated to be 70-90%.

Protein Binding: PPA is minimally bound to plasma proteins, with approximately 20% binding in dogs.

Available Formulations & Strengths

Oral Tablet 25 mg, 50 mg, 75 mg (PO)

Oral Capsule 25 mg, 50 mg (PO)

Oral Liquid/Syrup 6.25 mg/mL, 12.5 mg/mL (PO)

Chewable Tablet 25 mg, 50 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to phenylpropanolamine or other sympathomimetics
Severe hypertension
Cardiovascular disease (e.g., arrhythmias, coronary insufficiency)
Hyperthyroidism
Diabetes mellitus (may exacerbate hyperglycemia)
Glaucoma (angle-closure)
Concurrent use with monoamine oxidase inhibitors (MAOIs)
Concurrent use with other sympathomimetics (e.g., ephedrine, pseudoephedrine)

Warnings & Clinical Precautions:

Use with caution in animals with renal impairment, as drug excretion may be reduced.
Use with caution in animals with a history of seizures, as PPA may lower the seizure threshold.
Monitor blood pressure in animals with pre-existing hypertension.
In cats, use with extreme caution due to increased sensitivity to sympathomimetic effects; monitor for signs of agitation, tachycardia, and hypertension.
May cause anorexia and weight loss; monitor body condition in animals on long-term therapy.
Safety in pregnant or lactating animals has not been established; use only when clearly needed.
Do not use in animals with pheochromocytoma.
Avoid use in animals with urinary obstruction or bladder stones, as increased urethral tone may worsen obstruction.

Adverse Effects & Reactions

Common:

Restlessness
Irritability
Anorexia
Vomiting
Diarrhea
Tachycardia
Mydriasis

Serious / Severe:

Hypertension
Cardiac arrhythmias
Seizures
Cerebral hemorrhage (rare)
Pulmonary edema (rare)

Rare:

Allergic reactions (urticaria, angioedema)
Hepatotoxicity (reported in humans; rare in animals)
Behavioral changes (aggression)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Monoamine oxidase inhibitors (MAOIs)	Risk of hypertensive crisis and hyperpyrexia; concurrent use is contraindicated.	High
Other sympathomimetics (e.g., ephedrine, pseudoephedrine)	Additive cardiovascular effects, increased risk of hypertension and arrhythmias.	High
Beta-blockers (e.g., propranolol)	May potentiate alpha-adrenergic effects, leading to unopposed vasoconstriction and severe hypertension.	Moderate
Tricyclic antidepressants (e.g., amitriptyline)	May enhance sympathomimetic effects, increasing risk of cardiac arrhythmias and hypertension.	Moderate
Digoxin	Increased risk of arrhythmias due to combined effects on cardiac excitability.	Moderate
Inhalation anesthetics (e.g., halothane)	Increased risk of ventricular arrhythmias due to sensitization of myocardium to catecholamines.	Moderate
Oxytocin	Potential for severe hypertension when used concurrently.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypertension
Tachycardia or bradycardia (reflex)
Cardiac arrhythmias
Agitation, tremors, seizures
Hyperthermia
Mydriasis
Respiratory distress
Cerebral hemorrhage (in severe cases)

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and animal is stable. Administer activated charcoal to reduce absorption. Control seizures with diazepam or barbiturates. Manage hypertension with alpha-adrenergic blockers (e.g., phentolamine) or vasodilators (e.g., nitroprusside). Treat arrhythmias with appropriate antiarrhythmic agents. Monitor vital signs, ECG, and blood pressure. Provide fluid therapy as needed, but avoid overhydration. In severe cases, consider intensive care.

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is prohibited or strictly regulated.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Keep container tightly closed. Protect from moisture. Keep out of reach of children and animals.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs for urinary incontinence (e.g., Proin®). Not approved for cats or other species.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited under AMDUCA because PPA is not approved for food animals and no withdrawal times are established. In companion animals, extra-label use is permitted under veterinary discretion.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Phenylpropanolamine is the first-line treatment for urethral sphincter hypotonus (USH) in dogs, a common cause of urinary incontinence in spayed females. It is generally well-tolerated, but adverse effects such as restlessness and hypertension can occur. Dose titration is important to achieve continence while minimizing side effects. In cats, use is off-label and should be approached with caution due to increased sensitivity to sympathomimetics. PPA should not be used in animals with cardiovascular disease, hypertension, or hyperthyroidism. For animals that do not respond to PPA alone, combination therapy with estrogen (e.g., diethylstilbestrol) or other agents may be considered. Regular monitoring of blood pressure and renal function is recommended for long-term therapy. Client education should emphasize the importance of consistent dosing and reporting any signs of agitation, vomiting, or changes in behavior.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)